Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal drug delivery technology. The company says, “This validates the novelty of the company’s innovative and pioneering efforts in identifying a ‘right-of-way’ for administering therapeutic formulations from a defined vantage point within the nasal anatomy.”
In 2025, the company received US Patent No. 12,343,489, titled, “Intranasal and olfactory delivery devices and methods of use” shortly after announcing a partnership with CDMO Kindeva for development of its “Olfactory Delivery Device,” which is intended to deliver drug to the olfactory clefts.
Rocket Science Health President Sohier Hall commented, “We don’t think of this as complicated. It’s a practical solution to a basic problem: if a therapy needs to reach a specific biological target, the method of administration has to get it there reliably. This patent secures the place in the anatomy where that becomes possible.”
Read the Rocket Science Health press release
